ProCE Banner Activity

ExpressPoints: Addressing the Medical Need in CLL: How BTK Inhibitors Are Improving Outcomes

Slideset Download
Download this short summary slideset of key takeaways from a live CCO Webinar focused on key data for using BTK inhibitors in patients with CLL.

Released: December 09, 2020

Expiration: December 08, 2021

No longer available for credit.

Share

Faculty

Ian W. Flinn

Ian W. Flinn, MD, PhD

Chief Scientific Officer
One Oncology and Tennessee Oncology
Nashville, Tennesse

Susan M. O Brien

Susan M. O Brien, MD

Professor of Medicine
Department of Leukemia
University of Texas M.D. Anderson Cancer Center
Houston, Texas

John Pagel

John Pagel, MD, PhD

Associate Professor
Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle, Washington

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

BeiGene, Ltd.

Faculty Disclosure

Primary Author

Ian W. Flinn, MD, PhD

Chief Scientific Officer
One Oncology and Tennessee Oncology
Nashville, Tennesse

Ian W. Flinn

Susan M. O Brien, MD

Professor of Medicine
Department of Leukemia
University of Texas M.D. Anderson Cancer Center
Houston, Texas

John Pagel, MD, PhD

Associate Professor
Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle, Washington